STEVE ASELAGE - 14 Mar 2023 Form 4 Insider Report for Acer Therapeutics Inc.

Role
Director
Signature
/s/ Harry S. Palmin, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
14 Mar 2023
Net transactions value
$0
Form type
4
Filing time
16 Mar 2023, 16:30:19 UTC
Previous filing
01 Dec 2022
Next filing
15 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACER Stock Option (right to buy) Award $0 +20,000 $0.000000 20,000 14 Mar 2023 Common Stock 20,000 $1.67 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option, which is made as part of the Issuer's 2023 annual compensation cycle, vests and becomes exercisable in full on March 14, 2024.